Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) saw unusually large options trading on Friday. Stock traders acquired 4,870 put options on the company. This is an increase of approximately 78% compared to the average daily volume of 2,737 put options.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA trial met the overall survival primary endpoint for relacorilant in platinum‑resistant ovarian cancer — a clear clinical validation that can materially expand the drug’s commercial and regulatory prospects and explains the sharp buying interest. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial
• Positive Sentiment: Wide media and analyst coverage amplified the trial news, helping drive momentum and volume as investors reassess the company’s valuation and pipeline upside. Corcept’s cancer drug meets main goal in late-stage trial — Reuters
• Positive Sentiment: Analyst support increased: Canaccord raised its price target to $100 and maintained a buy rating, signalling institutional conviction that the ROSELLA result changes the firm’s outlook. CORT price target raised at Canaccord — The Fly
• Neutral Sentiment: Multiple outlets reported the survival benefit (Benzinga, Investing.com, Seeking Alpha, MSN), increasing visibility but not yet translating into regulatory approvals or sales — next steps (regulatory filing strategy, subgroup data, safety details) will determine sustainable upside. Corcept experimental drug cuts death risk — Benzinga
• Negative Sentiment: Shareholder litigation and investigations (Hagens Berman, Pomerantz) into prior disclosures remain active. These probes relate to the December FDA CRL for relacorilant in Cushing’s syndrome and the dramatic December share drop, which pose legal and disclosure risk and could create uncertainty or liabilities. Hagens Berman investigation alert — PR Newswire
• Negative Sentiment: The earlier FDA complete response letter for relacorilant in Cushing’s syndrome remains an unresolved regulatory setback; while the ovarian cancer success helps, approval pathways and timing for different indications are distinct and uncertain. Pomerantz investigation alert — PR Newswire

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CORT shares. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. Canaccord Genuity Group upped their price objective on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, HC Wainwright upped their price objective on Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $83.50.

Insiders Place Their Bets

In other news, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $73.65, for a total transaction of $368,250.00. Following the transaction, the insider owned 10,277 shares in the company, valued at $756,901.05. This trade represents a 32.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Joseph K. Belanoff sold 40,000 shares of Corcept Therapeutics stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the completion of the sale, the chief executive officer directly owned 2,701,370 shares in the company, valued at $215,488,284.90. This represents a 1.46% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 194,500 shares of company stock worth $14,186,410. 20.80% of the stock is owned by company insiders.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its position in Corcept Therapeutics by 18.9% during the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after purchasing an additional 2,444 shares in the last quarter. Amundi purchased a new position in Corcept Therapeutics in the 1st quarter valued at about $450,000. NewEdge Advisors LLC purchased a new stake in shares of Corcept Therapeutics during the first quarter worth about $518,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Corcept Therapeutics by 71.6% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 13,647 shares of the biotechnology company’s stock worth $986,000 after acquiring an additional 5,693 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Corcept Therapeutics by 277.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 910 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 669 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

CORT traded up $1.57 during midday trading on Friday, reaching $42.87. 605,263 shares of the company’s stock were exchanged, compared to its average volume of 2,545,622. Corcept Therapeutics has a 1-year low of $32.99 and a 1-year high of $117.33. The stock has a market capitalization of $4.51 billion, a PE ratio of 48.72 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. The business’s 50-day moving average price is $65.87 and its 200 day moving average price is $71.26.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The business had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. During the same period last year, the business earned $0.41 earnings per share. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. As a group, equities analysts anticipate that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.